Bevacizumab Reduces Epistaxis‐Related Operative Burden in Hereditary Hemorrhagic Telangiectasia
0 citations
Abstract
Key Points Bevacizumab reduced epistaxis‐related ablation frequency by 55.6% in HHT patients. Over half of HHT patients (57.7%) required no ablation intervention after bevacizumab initiation. Maintenance bevacizumab dosing remains highly variable, underscoring the need for standardization.
// Source
Authors: Nathan R. Barefoot, Priya J. Desai, Anna Van Dorsten, Elena Quinonez Del Cid, Katrina Bootes, Ismail M. Khaderi, Ezer H. Benaim, Jackson Vuncannon, Cristine Klatt-Cromwell, Charles S. Ebert, Raj S. Kasthuri, Brent A. Senior, Brian D. Thorp, Adam J. Kimple
Institutions: University of North Carolina at Chapel Hill